Health Economics and Outcomes Research
Novosys Health provides premier quality research in health economics and outcomes research and clinical trial analytics that helps quantify and demonstrate the full value of pharmaceutical and other medical products. We help to use real-world and trial data to illustrate the clinical and economic benefits and values of healthcare products to payers, clinical providers, patients and policy makers. Our team possesses expertise in a broad range of real-world health economics and outcomes research topics, including retrospective database analysis, disease burden evaluation, health economic modeling, cost-effective analysis and comparative effectiveness reviews in numerous therapeutic areas.
Retrospective database analysis
Clinical trials demonstrate the efficacy and safety of interventions in a controlled environment where patients are closely monitored. Real-world treatment outcomes may not reflect those of a clinical trial since variables such as patient characteristics and compliance can't be controlled. Healthcare databases provide a wealth of information that can be used to assess the efficacy and safety of treatment interventions in the real-world setting. Novosys Health has extensive expertise with numerous administrative databases and our team members can effectively design and execute your study, delivering high quality research in a timely manner.
Healthcare burden of dyspepsia among nonvalvular atrial fibrillation patients. J Manag Care Pharm. Accepted 2013
Hospitalization resource utilization and costs among Medicaid insured patients with schizophrenia with different treatment durations of long-acting injectable antipsychotic therapy. J Clin Pharmacol. 2013
Real-world treatment pattern and outcomes among patients who took tapentadol IR or oxycodone IR. J Med Econ. 2013
Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia. Adv Ther. 2013
Rate of deep-vein thrombosis and pulmonary embolism during the care continuum in patients with acute ischemic stroke in the United States. BMC Neurology. 2013
Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. Lung Cancer. 2012
Meta-analysis and systematic review
Novosys Health's team members have advanced graduate degrees and research skills that allow them to successfully synthesize high quality research evidence and perform systematic reviews and meta-analyses. We also perform systematic literature reviews to generate further evidence to raise either disease or product awareness.
Meta-analysis of randomized controlled trials of lixisenatide as add-on to basal insulin ± OADs in patients with type 2 diabetes mellitus. The Annual Scientific Meeting of the Australian Diabetes Society and Australian Diabetes Educators Association, 2013
Meta-analysis of GLP-1 agonist lixisenatide use in patients insufficiently controlled with oral antidiabetic drugs suggest improved results in efficacy, hypoglycemia and weight gain. American Diabetes Association (ADA) Annual Meeting, 2013
Meta-analysis of randomized controlled trials of lixisenatide as add-on to basal insulin in patients with type 2 diabetes mellitus. American Diabetes Association (ADA), 2013
Meta-analysis of efficacy and safety outcomes associated with the basal-plus regimen of insulin glargine and insulin glulisine among type 2 diabetes patients with HbA1c ≥8%. American Diabetes Association (ADA) Annual Conference, 2012
Meta-analysis of maternal and neonatal outcomes associated with the use of insulin glargine versus NPH insulin during pregnancy. Obstet Gynecol Int. 2012
Mixed treatment comparison
Mixed treatment comparisons, also known as indirect treatment comparisons and network or multiple-treatments meta-analyses, allow for the comparison of treatment interventions where little or no evidence is available from head to head randomized clinical trials. Our team members have experience with this recent advance in meta-analysis methodology, from the collection of all available evidence to performing the analysis.
Health economic modeling and cost-effective analysis
With rising healthcare costs the need to identify the treatment interventions that provide the greatest benefit for the least cost has become critical as decision-makers allocate the resources of shrinking budgets. As a result, cost-effectiveness analyses and health economic modeling have become essential methods of assessing the costs and health benefits of an intervention. Novosys Health has performed cost-effectiveness analyses and developed economic models for treatment interventions in a wide range of therapeutic areas. From design to execution, our team members will deliver top-quality research and excellent service.
Medical costs of oral anticoagulants vs warfarin for atrial fibrillation patients with different stroke risks. Cardiol Therapy. 2013
Comparison of medical costs of atrial fibrillation patients unsuitable for warfarin treated with apixaban or aspirin, based on AVERROES trial. Clin Appl Thromb Hemost. 2013
Estimation of potential cost savings associated with reduced rates of cardiovascular hospitalization among atrial fibrillation/flutter patients treated with dronedarone in the ATHENA trial. Am J Ther. 2013
Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials. Hosp Pract (Minneap). 2012
Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial. J Med Econ. 2012
Economic model interfaces and apps
When assessing the economic impact of a treatment or intervention, the ability to dynamically visualize the effect of changing various model parameters is of great benefit. The prevalence of smartphones and tablets in business allows for the use of interfaces and apps to access data and present the results of economic models. Novosys Health creates model interfaces and web-enabled apps that allow the user to customize and report diverse types of data.
Select interfaces and apps: